PRESS RELEASE published on 07/09/2026 at 08:00, 1 month 1 day ago Pentixapharm Receives FDA Fast Track Designation for Phase 3 Diagnostic Candidate [⁶⁸Ga]Ga-PentixaFor in Primary Aldosteronism Pentixapharm Holding AG granted FDA Fast Track designation for [⁶⁸Ga]Ga-PentixaFor diagnostic candidate in primary aldosteronism. Fast Track streamlines regulatory process & interaction with FDA FDA Fast Track Pentixapharm Primary Aldosteronism Regulatory Milestone Diagnostic Candidate
BRIEF published on 07/09/2026 at 07:08, 1 month 1 day ago Pentixapharm Holding AG obtient la procédure accélérée de la FDA pour son candidat diagnostic Procédure Accélérée De La FDA Aldostéronisme Primaire Examen Réglementaire Étude PANDA [68Ga]Ga-PentixaPour
BRIEF published on 07/09/2026 at 07:08, 1 month 1 day ago Pentixapharm Holding AG Secures FDA Fast Track for Diagnostic Candidate FDA Fast Track Primary Aldosteronism Regulatory Review PANDA Study [68Ga]Ga-PentixaFor
PRESS RELEASE published on 07/09/2026 at 07:03, 1 month 1 day ago EQS-Adhoc: Pentixapharm Holding AG: Pentixapharm Receives FDA Fast Track Designation for [⁶⁸Ga]Ga-PentixaFor for the Subtyping of Primary Aldosteronism Pentixapharm Holding AG receives FDA Fast Track designation for [⁶⁸Ga]Ga-PentixaFor for subtyping of Primary Aldosteronism, allowing more efficient regulatory review process FDA Fast Track Primary Aldosteronism Pentixapharm Holding AG [68Ga]Ga-PentixaFor Subtyping
BRIEF published on 07/01/2026 at 15:32, 1 month 9 days ago Pentixapharm lance une levée de fonds pour financer la phase 3 de son essai clinique PANDA et sa croissance aux États-Unis. Augmentation De Capital Pentixapharm Émission De Droits Expansion Américaine PANDA Phase 3
BRIEF published on 07/01/2026 at 15:32, 1 month 9 days ago Pentixapharm Initiates Capital Expansion for PANDA Phase 3 and U.S. Growth Capital Increase Rights Issue U.S. Expansion Pentixapharm PANDA Phase 3
PRESS RELEASE published on 07/01/2026 at 15:27, 1 month 9 days ago Pentixapharm Launches Rights Issue to Fund PANDA Phase 3 and U.S. Expansion Pentixapharm launches rights issue to fund PANDA Phase 3 study and U.S. expansion, major shareholder commits to full exercise of subscription rights Capital Increase Rights Issue U.S. Expansion Pentixapharm PANDA Phase 3
BRIEF published on 07/01/2026 at 12:10, 1 month 9 days ago Pentixapharm Holding AG Plans Rights Issue to Raise EUR 20.4 Million Capital Increase Rights Issue Subscription Price PANDA Phase 3 Study Eckert Wagniskapital
BRIEF published on 07/01/2026 at 12:10, 1 month 9 days ago Pentixapharm Holding AG prévoit une augmentation de capital par émission de droits pour lever 20,4 millions d'euros. Augmentation De Capital Émission De Droits Prix De L'abonnement Eckert Wagniskapital Étude PANDA De Phase 3
PRESS RELEASE published on 07/01/2026 at 12:05, 1 month 9 days ago EQS-Adhoc: Pentixapharm Holding AG: Resolves on Rights Issue with an Offering Volume of up to Appr. EUR 20.4 Million; Major Shareholder Eckert Wagniskapital Commits to Fully Exercise Its Subscription Rights Pentixapharm Holding AG resolves on rights issue worth up to EUR 20.4 million; Eckert Wagniskapital to fully exercise subscription rights for new shares, supporting corporate development and PANDA Phase 3 study Rights Issue Subscription Rights Pentixapharm Holding AG PANDA Phase 3 Study Eckert Wagniskapital
Published on 08/10/2026 at 15:30, 4 hours 2 minutes ago Silver Spruce Resources, Inc. Announces New Chief Financial Officer
Published on 08/10/2026 at 15:25, 4 hours 7 minutes ago Gemdale Gold Intersects 5.19m at 14.01 g/t Au within 110m at 1.18 g/t Au at the Pontio Gold Project, Finland
Published on 08/10/2026 at 14:30, 5 hours 2 minutes ago NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
Published on 08/10/2026 at 13:30, 6 hours 2 minutes ago Sterling Expands High-Grade Copper Mineralization East at MEPS Intersecting 203 Metres at 0.51% CuEq: Includes 16.25 Metres at 2.31% CuEq and 9.50 Metres at 2.34% CuEq within 445 Metres at 0.40% CuEq
Published on 08/10/2026 at 13:00, 6 hours 32 minutes ago Alaska Energy Metals Announces Drilling Program for the Mcbride Prospect, Angliers-Belleterre Project, Quebec, Canada
Published on 08/10/2026 at 19:00, 32 minutes ago PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 03 AOUT 2026 au 07 AOUT 2026
Published on 08/10/2026 at 18:29, 1 hour 2 minutes ago Fuller, Smith & Turner PLC: Director/PDMR Shareholdings
Published on 08/10/2026 at 17:50, 1 hour 42 minutes ago Disclosure according to Article 5(1)(b) of the EU Regulation No. 596/2014 and Article 2(3) of the Delegated EU Regulation No. 2016/1052 - 1st Interim Report
Published on 08/10/2026 at 17:38, 1 hour 54 minutes ago PATRIZIA delivers strong earnings growth with EUR 42.7m EBITDA (+46.6% y-o-y) in H1 2026
Published on 08/10/2026 at 17:11, 2 hours 21 minutes ago CORRECTION FROM SOURCE: North Peak Commences 2026 Drilling Campaign at Prospect Mountain, Eureka, Nevada
Published on 08/10/2026 at 18:00, 1 hour 32 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 1 hour 32 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Published on 08/10/2026 at 11:53, 7 hours 38 minutes ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026